Article metrics

Download PDFPDF

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

 

Online download statistics by month:

Online download statistics by month: June 2018 to June 2021

AbstractFullPdf
Jun 2018748755271
Jul 201828182875384
Aug 201815341535322
Sep 2018796796207
Oct 2018531531163
Nov 2018461461133
Dec 201830630677
Jan 201934233994
Feb 201933030578
Mar 2019326321122
Apr 2019402373114
May 201928827659
Jun 201922321867
Jul 201928527562
Aug 201922321173
Sep 201918016167
Oct 201921918876
Nov 201915715259
Dec 201915014445
Jan 202022921375
Feb 202017114950
Mar 202014012954
Apr 202016014665
May 202015914341
Jun 202011510270
Jul 202014312556
Aug 202012311763
Sep 202017115498
Oct 202017916594
Nov 202017916582
Dec 202015914348
Jan 202117315349
Feb 202121319062
Mar 202119316959
Apr 202119115766
May 202116513948
Jun 202117616061
Total13358129413614